Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

Astellas

Status: Completed

Conditions: Prostate Cancer

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT06500741

9785-MA-3547

Details and patient eligibility

About

The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the United States (US), Germany, Spain, France, Italy, the United Kingdom (UK), South Korea, Australia, and Brazil, using a discrete choice experiment (DCE).

Full description

The study will collect data from eligible patients (six total) and physicians (six total) from one-on-one qualitative interviews and eligible patients from online surveys. Approximately 330 patients with PC will be recruited to complete the online DCE survey.

Enrollment: 374 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Physician inclusion criteria

• The physician is a certified urologist or oncologist. The final selection will be adjusted to local practice.
• The physician has cared for at least ten nmHSPC patients in the past year.
• The physician has experience prescribing NHT and ADT. Patient inclusion criteria
• The patient has nmHSPC after radiotheraphy (RT) and/or radical prostatectomy (RP), defined as an adult patient with nmPC who had RT and/or RP.

Exclusion criteria

Physician exclusion criteria

• None Patient exclusion criteria
• The patient is castration resistant.
• The patient has metastatic PC.

Trial design

374 participants in 1 patient group

Participants

Description:

Participants will include urologists or oncologists for the physician interviews and prostate cancer patients for the patient interviews and surveys.

Treatment:

Other: No Intervention